Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

The development of gastrointestinal stromal tumors (GISTs) is largely driven by mutations in the KIT and PDGFRα genes. Imatinib mesylate is an oral small molecular tyrosine kinase inhibitor that mainly targets abl, c-KIT, and PDGFRα. Imatinib achieves disease control in approximately 70%–85% of pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Spitaleri, Gianluca, Biffi, Roberto, Barberis, Massimo, Fumagalli, Caterina, Toffalorio, Francesca, Catania, Chiara, Noberasco, Cristina, Lazzari, Chiara, de Marinis, Filippo, De Pas, Tommaso
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2015
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4548749/
https://ncbi.nlm.nih.gov/pubmed/26316776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S81558
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados